{"filings":[{"id":92785,"accession_number":"0001104659-26-056782","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR","event_type":"earnings","confidence":"high","bullets":["Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.","FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.","Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.","Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.","UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":71430000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103904,"accession_number":"0001104659-26-032774","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Wendy Yarno to retire from Iovance board at 2026 annual meeting","event_type":"leadership","confidence":"high","bullets":["Wendy Yarno will retire and not stand for re-election at the June 2026 annual meeting.","Yarno will serve out her current director term until the annual meeting.","Retirement is not due to any disagreement with the company on operations, policies, or practices.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103903,"accession_number":"0001104659-26-018837","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.","Gross margin improved to ~50% in Q4; cash $303M funds operations into Q3 2027.","FDA Fast Track granted for lifileucel in second-line advanced nonsquamous NSCLC; potential launch 2H27.","Real-world Amtagvi ORR ~44% at Tandem Meetings; 52% in patients with ≤2 prior lines.","Sarcoma early data: 50% ORR (6 evaluable); registrational trial to start Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":263502000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103902,"accession_number":"0001104659-26-002323","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3","event_type":"other_material","confidence":"high","bullets":["Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.","Cash position of $307M as of 9/30/25, expected to fund operations into Q2 2027.","85 authorized treatment centers as of 12/31/25; over 1,000 patients treated with commercial and clinical TIL products.","Gross margin of 43% in Q3 2025; organization streamlined in Q3 2025 to support improved margins.","IOV-LUN-202 NSCLC trial enrollment complete; data update expected in 2026 with potential launch in H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120183,"accession_number":"0001104659-25-107426","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable","event_type":"earnings","confidence":"high","bullets":["Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.","Cash and investments ~$307M; expected to fund operations into Q2 2027.","Full-year 2025 revenue guidance reaffirmed at $250-300M.","Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.","Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":176731000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136749,"accession_number":"0001104659-25-085650","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance posts updated corporate presentation for August 2025; no specific details disclosed","event_type":"other_material","confidence":"low","bullets":["Company filed an 8-K announcing a revised corporate presentation dated August 2025.","Presentation is used at healthcare conferences and for discussions with analysts and stockholders.","Exhibit 99.1 incorporated by reference but full content not provided in this filing excerpt.","No financial or clinical milestones were explicitly stated in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136748,"accession_number":"0001104659-25-081953","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.","Jefferies will receive 3.0% commission on gross proceeds from any shares sold.","Sales may be made from time to time at the Company's discretion; no obligation to sell.","Prospectus supplement dated August 22, 2025, filed under existing S-3ASR registration statement.","Agreement is an amendment and restatement of prior open market sale agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136747,"accession_number":"0001104659-25-080304","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iovance's Amtagvi receives Health Canada approval for advanced melanoma","event_type":"regulatory","confidence":"high","bullets":["Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.","First marketing authorization outside the U.S.; first T cell therapy approved for a solid tumor cancer in Canada.","Approval based on Phase 2 C-144-01 trial ORR and DOR by IRC; results published in 2022 and 2025 journals.","Iovance expects to authorize first Canadian treatment center within next few months; advancing ex-U.S. strategy.","Amtagvi is also being investigated in frontline advanced melanoma (Phase 3 TILVANCE-301) and other solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136746,"accession_number":"0001104659-25-075175","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.","Reiterated FY2025 total product revenue guidance of $250M-$300M.","Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.","Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.","Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":109276000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136745,"accession_number":"0001104659-25-067940","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Iovance appoints Corleen Roche as CFO effective August 6, 2025","event_type":"leadership","confidence":"high","bullets":["Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.","Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.","Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.","Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136744,"accession_number":"0001104659-25-065781","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO","event_type":"leadership","confidence":"high","bullets":["CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.","Matthew W. Rosinack appointed interim Principal Financial Officer and Principal Accounting Officer effective June 30, 2025.","Rosinack has been SVP, Finance since Sept 2021; prior roles at Berkeley Lights, ZELTIQ Aesthetics, FormFactor, and PwC.","No arrangements, family relationships, or transactions requiring disclosure in connection with Rosinack's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153983,"accession_number":"0001104659-25-059464","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025","event_type":"leadership","confidence":"high","bullets":["Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.","No replacement named; company states departure is to pursue other opportunities.","Frederick G. Vogt serves as Interim CEO and President; CFO role remains unfilled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153982,"accession_number":"0001104659-25-058199","cik":1425205,"company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting","event_type":"other_material","confidence":"high","bullets":["Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.","All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).","Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.","Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.","Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}